Japanese pharma firm Shionogi has unveiled plans to establish a new wholly-owned manufacturing subsidiary effective October 1, 2018. The new business venture will be in charge of manufacturing functions in the Shionogi group.

In addition, the company says the new manufacturing subsidiary will develop contract businesses including the manufacture of investigational drug products, analytical testing, pharmaceutical engineering, as well as commercial contract pharmaceutical manufacturing.

Operations of the new manufacturing subsidiary will start on April 1, 2019.